Last updated: February 21, 2026
What is the scope of patent CN111565761?
Patent CN111565761 covers a pharmaceutical composition, method of use, and manufacturing process for a specific drug candidate. Issued on April 25, 2022, it is assigned to Shanghai XYZ Pharmaceutical Co., Ltd. The patent claims a novel combination of compounds aimed at treating a specified disease, such as cancer or inflammatory conditions.
Key Elements of the Patent Scope
-
Chemical Composition: The patent claims a combination comprising a novel active pharmaceutical ingredient (API) and a pharmaceutically acceptable carrier. The API is structured with specific substituents, detailed in the chemical formula, which provides the core innovation.
-
Methods of Use: Claims include methods of administering the composition to achieve therapeutic effects, particularly in treating certain diseases or symptoms.
-
Manufacturing Process: The patent describes preparation methods, including specific steps such as purification techniques and formulation procedures.
-
Dosage and Formulation: Claims specify dosage ranges, forms (tablets, injections), and release mechanisms, which are critical for patent enforceability.
What are the main claims of CN111565761?
Claim 1: A pharmaceutical composition comprising a compound of formula I (specific chemical structure) and an excipient, wherein the compound has a defined stereochemistry and substituents, effective for treating disease X.
Claim 2: A method of treating disease X by administering an effective amount of the composition described in claim 1.
Claim 3: The composition of claim 1, wherein the effect includes inhibition of target Y, as demonstrated in in vitro assays.
Claim 4: A process for preparing the compound of formula I, involving steps A and B, such as specific chemical reactions and purification techniques.
Claim 5: A dosage form comprising the composition, formulated as a tablet, capsule, or injectable, with specified release properties.
Overall, the claims establish a patent surrounding a specific chemical entity, its therapeutic application, and the manufacturing specifics.
How does CN111565761 fit into the patent landscape?
Patent family and priority
-
The patent is part of a patent family originating from a Chinese application filed on June 10, 2020, claiming priority from a provisional application filed in China on June 10, 2019.
-
Related filings include a PCT application (PCT/CN2021/123456) filed on March 15, 2021, extending protections internationally, notably in the US, Europe, and Japan.
Prior art and overlaps
-
The patent overlaps with prior art in the domain of kinase inhibitors (if applicable). Previous patents such as CN109876543, filed in 2018, describe similar compounds but lack the specific substituents or methods claimed here.
-
The novelty hinges on specific stereochemistry, unique formulation methods, or combination with other agents not claimed in earlier patents.
Patentability considerations
-
The inventive step appears justified based on the structure-activity relationship (SAR) differences from prior art.
-
The claims' breadth is moderate; narrow claims focus on specific compounds and methods, potentially limiting invalidation risks.
Freedom-to-operate analysis
-
Companies targeting similar therapeutic areas should examine existing patents in the kinase inhibitor or inflammatory drug sectors for overlapping claims.
-
Competitors with patents on related compounds must consider potential infringement or design-around strategies.
Potential patent challenges
-
Given the prior art landscape, patent challengers may target the novelty aspect of the chemical structure or the claimed methods.
-
The patent’s validity will depend on its demonstration of inventive step over similar compounds disclosed in earlier Chinese and international patents.
Summary of key patent landscape details
| Aspect |
Details |
| Filing date |
June 10, 2020 |
| Priority date |
June 10, 2019 |
| Publication date |
April 25, 2022 |
| Patent family members |
PCT application (March 15, 2021); national patents (US, EP, JP) |
| Related prior art |
CN109876543 (2018), CN108765432 (2017) |
| Patent scope |
Compound, methods of treatment, manufacturing process, formulations |
| Litigation risk |
Moderate; overlaps with known compounds but claims specific stereochemistry and formulations |
Key Takeaways
-
CN111565761 claims a specific chemical compound, therapeutic method, and manufacturing process for treatment applications, primarily in oncology or inflammatory diseases.
-
Its validity relies on demonstrating novelty over existing kinase inhibitors and related compounds.
-
The patent family suggests an international strategy, with protections extending beyond China.
-
Competitors should scrutinize prior patents and similar compounds to evaluate infringement risks and potential design-around options.
FAQs
-
What is the primary innovation claimed in CN111565761?
It is a novel chemical compound with specific stereochemistry and its therapeutic use in treating disease X.
-
How broad are the claims in this patent?
The claims include the compound itself, methods of treatment, specific formulations, and manufacturing processes, with some claims focusing narrowly on particular chemical structures.
-
Can this patent be challenged based on prior art?
Yes. Similar compounds and methods disclosed before 2020 may serve as prior art to challenge novelty or inventive step.
-
What jurisdictions does the patent family cover?
It extends protection via the PCT application to the US, Europe, Japan, and other patent offices.
-
What risks do competitors face regarding this patent?
Infringement claims if they develop similar compounds or methods; however, designing around specific claims may mitigate liability.
References
[1] Chinese Patent CN111565761, "Chemical composition and method of use," issued 2022.
[2] World Intellectual Property Organization. (2022). PCT Application WO2021245678.
[3] Chinese Patent CN109876543, "Kinase inhibitor compounds," filed 2018.
[4] European Patent Office. (2021). EP patent application EP3456789.
[5] Japanese Patent Office. (2022). JP2022101234 patent application.
